MedTrace Logo

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

NCT03198130 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-03-19

No results posted yet for this study

Summary

This study is being conducted to compare the relationship of patient response to treatment to changes in tumor microenvironment.

Conditions

  • Recurrent Squamous Cell Carcinoma of Head
  • Recurrent Squamous Cell Carcinoma of Neck
  • Metastatic Squamous Cell Carcinoma of Head
  • Metastatic Squamous Cell Carcinoma Neck

Interventions

DRUG

REGN2810

Intravenous (IV) use

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-03
Primary Completion
2019-06-27
Completion
2020-02-21
FDA Drug
Yes

Countries

  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03198130 on ClinicalTrials.gov